Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD33-CLL-1 CAR-NK cells
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-CD33-CLL-1 CAR-NK cells are an investigational cell therapy consisting of natural killer (NK) cells genetically engineered to express a bispecific chimeric antigen receptor (CAR) targeting both CD33 and C-type lectin-like molecule-1 (CLL-1/CLEC12A). Developed by The Affiliated Hospital of Xuzhou Medical University, this therapy is primarily aimed at treating relapsed or refractory acute myeloid leukemia (AML). CD33 is widely expressed on AML blasts, while CLL-1 is expressed on both AML blasts and leukemic stem cells (LSCs) but absent on healthy hematopoietic stem cells, making them ideal targets for dual-antigen recognition to minimize off-target effects and prevent antigen-escape-mediated relapse. The use of NK cells as a vehicle for the CAR construct may offer advantages over T-cell-based therapies, such as a lower risk of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS).
- Other names
- CD33/CLL-1 bispecific CAR-NK cellsCLL-1/CD33 CAR-NK cellsanti-CD33/CLL-1 CAR-NK cells
02
Targets
CD33 (Myeloid cell surface antigen CD33)CLEC12A
Beyond the preview
Go deeper on anti-CD33-CLL-1 CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD33-CLL-1 CAR-NK cells.